343 related articles for article (PubMed ID: 33847080)
21. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
[TBL] [Abstract][Full Text] [Related]
22. Mortality, liver transplantation and hepatic complications in patients with treatment-naïve chronic hepatitis B treated with entecavir vs tenofovir.
Kim BG; Park NH; Lee SB; Lee H; Lee BU; Park JH; Jung SW; Jeong ID; Bang SJ; Shin JW
J Viral Hepat; 2018 Dec; 25(12):1565-1575. PubMed ID: 29998592
[TBL] [Abstract][Full Text] [Related]
23. Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection.
Wang XH; Hu ZL; Fu YZ; Hou JY; Li WX; Zhang YJ; Xu L; Zhou QF; Chen MS; Zhou ZG
J Gastroenterol; 2022 Mar; 57(3):185-198. PubMed ID: 35152312
[TBL] [Abstract][Full Text] [Related]
24. Lower risk of hepatocellular carcinoma with tenofovir than entecavir in antiviral treatment-naïve chronic hepatitis B patients: a systematic review and meta-analysis involving 90,897 participants.
Shao J; Wang Y; Hu L; Zhang L; Lyu C
Clin Exp Med; 2023 Oct; 23(6):2131-2140. PubMed ID: 36648567
[TBL] [Abstract][Full Text] [Related]
25. Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B.
Kim YM; Shin HP; Lee JI; Joo KR; Cha JM; Jeon JW; Yoon JY; Kwak MS
Saudi J Gastroenterol; 2018; 24(6):326-335. PubMed ID: 30004042
[TBL] [Abstract][Full Text] [Related]
26. Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis.
Gu L; Yao Q; Shen Z; He Y; Ng DM; Yang T; Chen B; Chen P; Mao F; Yu Q
J Gastroenterol Hepatol; 2020 Sep; 35(9):1467-1476. PubMed ID: 32180249
[TBL] [Abstract][Full Text] [Related]
27. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
Choi J; Jo C; Lim YS
Hepatology; 2021 Feb; 73(2):661-673. PubMed ID: 32324905
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients.
Chon HY; Ahn SH; Kim YJ; Yoon JH; Lee JH; Sinn DH; Kim SU
Hepatol Int; 2021 Dec; 15(6):1328-1336. PubMed ID: 34799838
[TBL] [Abstract][Full Text] [Related]
29. Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
Shin JW; Jeong J; Jung SW; Lee SB; Park BR; Kim MJ; Park EJ; Park NH
Dig Dis Sci; 2021 May; 66(5):1739-1750. PubMed ID: 32524416
[TBL] [Abstract][Full Text] [Related]
30. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis.
Zhang Z; Zhou Y; Yang J; Hu K; Huang Y
BMC Cancer; 2019 May; 19(1):511. PubMed ID: 31142283
[TBL] [Abstract][Full Text] [Related]
31. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
Wang X; Liu X; Dang Z; Yu L; Jiang Y; Wang X; Yan Z
Gut Liver; 2020 Mar; 14(2):232-247. PubMed ID: 31158948
[TBL] [Abstract][Full Text] [Related]
32. No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis.
Yuan J; Peng Y; Hao FB; Wang YQ; Wang CR; Zhong GC
Aging (Albany NY); 2021 Feb; 13(5):7147-7165. PubMed ID: 33658397
[TBL] [Abstract][Full Text] [Related]
33. The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B.
Kim BG; Park NH; Lee SB; Jeon S; Park JH; Jung SW; Jeong ID; Bang SJ; Shin JW
Liver Int; 2018 Dec; 38(12):2269-2276. PubMed ID: 30052303
[TBL] [Abstract][Full Text] [Related]
34. Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis.
Li M; Lv T; Wu S; Wei W; Wu X; Ou X; Ma H; Chow SC; Kong Y; You H; Jia J
Hepatol Int; 2020 Jan; 14(1):105-114. PubMed ID: 31898210
[TBL] [Abstract][Full Text] [Related]
35. Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma.
Lee SW; Choi J; Kim SU; Lim YS
Clin Mol Hepatol; 2021 Jul; 27(3):402-412. PubMed ID: 34157830
[TBL] [Abstract][Full Text] [Related]
36. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.
Papatheodoridis GV; Dalekos GN; Yurdaydin C; Buti M; Goulis J; Arends P; Sypsa V; Manolakopoulos S; Mangia G; Gatselis N; Keskın O; Savvidou S; Hansen BE; Papaioannou C; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HL; Lampertico P
J Hepatol; 2015 Feb; 62(2):363-70. PubMed ID: 25195548
[TBL] [Abstract][Full Text] [Related]
37. Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study.
Kim SU; Seo YS; Lee HA; Kim MN; Lee EJ; Shin HJ; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
Cancer Epidemiol Biomarkers Prev; 2020 Apr; 29(4):832-837. PubMed ID: 31988073
[TBL] [Abstract][Full Text] [Related]
38. Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
Jeong S; Shin HP; Kim HI
Intervirology; 2022; 65(2):94-103. PubMed ID: 34731856
[TBL] [Abstract][Full Text] [Related]
39. Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir.
Chang JW; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Seo YS; Lee HA; Kim MN; Lee YR; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Park SY; Kim SU
J Viral Hepat; 2021 Jan; 28(1):95-104. PubMed ID: 33029863
[TBL] [Abstract][Full Text] [Related]
40. Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B.
Lee HW; Cho YY; Lee H; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK; Park SY
Hepatol Int; 2021 Oct; 15(5):1083-1092. PubMed ID: 34402025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
